Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

fast track appraisal

National Institute for Health and Care Excellence NICE logo

NICE recommends two drugs for ovarian cancer but rejects three

Paclitaxel and Caelyx given preliminary nod

National Institute for Health and Care Excellence NICE logo

BioMarin’s real world data sways NICE on orphan drug Vimizim

Rare genetic disorder treatment recommended in final draft guidance

EU flag

Wakix backed for European approval in narcolepsy

Bioprojet Pharma’s orphan drug given a positive opinion by CHMP

- PMLiVE

Cancer Drugs Fund overhaul promises faster access to drugs

Proposals suggest turning CDF into 'managed access' fund

- PMLiVE

Repatha’s price tag too rich for UK’s NICE

HTAbody turns the cholesterol-lowering antibody down in draft guidance

National Institute for Health and Care Excellence NICE logo

NICE backs four treatments for juvenile idiopathic arthritis

Includes BMS' Orencia and AbbVie's Humira

National Institute for Health and Care Excellence NICE logo

NICE backs use of anti-cholesterol drug Ezetrol

Draft guidance reflects 'greater emphasis on managing CVD risk'

- PMLiVE

Lundbeck sways NICE with new Brintellix data

Final draft guidance now backs the major depressive disorder drug

National Institute for Health and Care Excellence NICE logo

NICE to speed up adoption of health technologies

Launches new Office for Market Access

- PMLiVE

UK HCPs back transparency over their pharma payments

Survey comes as pharma companies prepare for payment disclosure database

National Institute for Health and Care Excellence NICE logo

NICE recommends Keytruda for advanced skin cancer

Second recommendation for drug in a week

ABPI’s Stephen Whitehead steps down

Leaves the UK pharma trade body after four years as its CEO

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links